DavidL.PalchakMD

Clinical Trials

• Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01

  Completed

  Phase 3

• Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2007 Mar 15

  Completed

  Phase 1, Phase 2

• Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15

  Completed

  Phase 2

• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01

  Active, not recruiting

  Phase 3

• Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2008 Apr 15

  Completed

  Phase 2

• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13

  Completed

  Phase 3

• Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 1996 May 01

  Active, not recruiting

• Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Start of enrollment: 2010 Jun 01

  Completed

  Phase 3

• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01

  Active, not recruiting

  Phase 3

• Vitamin D and Breast Cancer Biomarkers in Female Patients Start of enrollment: 2010 Oct 01

  Completed

  Phase 3

• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06

  Active, not recruiting

  Phase 3

• Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01

  Completed

  Phase 2

• MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10

  Completed

  Phase 2

• Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09

  Active, not recruiting

  Phase 3

• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25

  Completed

  Phase 2

• Join now to see all